help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, T. K.
Right arrow Articles by Rasmussen, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, T. K.
Right arrow Articles by Rasmussen, L. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 2 909-916
Copyright © 2004 by The Endocrine Society

Growth Hormone Increases Vascular Cell Adhesion Molecule 1 Expression: in Vivo and in Vitro Evidence

Troels Krarup Hansen, Sanne Fisker, Rolf Dall, Thomas Ledet, Jens Otto L. Jørgensen and Lars Melholt Rasmussen

Immunoendocrine Research Unit (T.K.H.), Medical Department M (Endocrinology and Diabetes) (T.K.H., S.F., R.D., J.O.L.J.), and Research Laboratory for Biochemical Pathology, Institute of Pathology (T.L., L.M.R.), University Hospital of Aarhus, Kommunehospitalet, DK-8000 Aarhus C, Denmark

Address all correspondence and requests for reprints to: Troels Krarup Hansen, M.D., Ph.D., Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Norrebrogade 42-44, DK-8000 Aarhus C, Denmark. E-mail: tkh{at}dadlnet.dk.

We investigated the impact of GH administration on endothelial adhesion molecules, vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, in vivo and in vitro. Soluble VCAM-1, E-selectin, and C-reactive protein concentrations were measured before and after treatment in 25 healthy subjects and 25 adult GH-deficient (GHD) patients randomized to GH treatment or placebo. Furthermore, we studied the direct effect of GH and IGF-I and serum from GH-treated subjects on basal and TNF{alpha}-stimulated expression of VCAM-1 and E-selectin on cultured human umbilical vein endothelial cells. Baseline levels of VCAM-1, but not E-selectin, were significantly lower in GHD patients than in healthy subjects (362 ± 15 µg/liter vs. 516 ± 21 µg/liter, P < 0.001) and increased in GHD patients during GH treatment, compared with placebo [net difference between groups 151.8 µg/liter (95% confidence interval: 95.0–208.7 µg/liter); P < 0.0001]. In human umbilical vein endothelial cells, there was no direct stimulatory effect of either GH or IGF-I on the expression of VCAM-1 and E-selectin, but serum from GH-treated healthy subjects significantly increased the expression of VCAM-1 (P < 0.01). Our findings are compatible with the notion that GH may stimulate the expression of VCAM-1 indirectly through modulation of circulating factors. VCAM-1-mediated leukocyte extravasation is implicated in several illnesses including atherosclerosis and multiple-organ failure in sepsis, and we hypothesize that enhanced expression of VCAM-1 may contribute to the detrimental effects of GH in critically ill patients.

This work was supported by grants from the Danish Research Council (Novo Nordisk Center for Research in Growth and Regeneration, Aarhus University, Grant 960082) and the Danish Heart Foundation.

Abbreviations: CRP, C-reactive protein; GHD, GH-deficient; HRP, horseradish-peroxidase; HUVEC, human umbilical vein endothelial cell;MOF, multiple-organ failure; VCAM-1, vascular cell adhesion molecule-1.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. Beauregard, A. L. Utz, A. E. Schaub, L. Nachtigall, B. M. K. Biller, K. K. Miller, and A. Klibanski
Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2063 - 2071.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Franco, B. Andersson, L. Lonn, B.-A. Bengtsson, J. Svensson, and G. Johannsson
Growth Hormone Reduces Inflammation in Postmenopausal Women with Abdominal Obesity: A 12-Month, Randomized, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2644 - 2647.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Colao, C. Di Somma, F. Rota, R. Pivonello, M. C. Savanelli, S. Spiezia, and G. Lombardi
Short-Term Effects of Growth Hormone (GH) Treatment or Deprivation on Cardiovascular Risk Parameters and Intima-Media Thickness at Carotid Arteries in Patients with Severe GH Deficiency
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2056 - 2062.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society